The Administrative Core is composed of Cancer Center Administration and Senior Leadership of the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The SKCCC Administration's purposes are to facilitate the overall planning, management and organization of the activities of the SKCCC, and to provide the support necessary to achieve and maintain the highest standards of cancer research excellence at the SKCCC. Administration is vital in assuring that the SKCCC achieves its goals and objectives and complies with NCI guidelines for Cancer Center Support Grants (CCSG). These goals are accomplished through an administrative infrastructure that enables streamlined and effective assistance to the Director, Senior Leaders, Program Leaders, Advisory Groups, Core Directors/Managers and general membership. SKCCC Administration provides the centralized management of resources and services required for the SKCCC's research activities, fiscal management and reporting functions. Coordinated activities include: participation in SKCCC governance and decision-making processes; representation of the SKCCC within the institution; oversight and management of CCSG relevant activities, including planning and evaluation oversight of Cores; faculty recruitment support; and management of the membership process and data, space, budgeting and finances, and the CCSG application. SKCCC Senior Leadership is responsible for overall planning and operational activities, administrative and management functions that support SKCCC research, and all scientific Program functions as described in detail throughout this CCSG application. The overall responsibility for planning and operation of research rests with the Director of the SKCCC, William G. Nelson, M.D., Ph.D. Dr. Nelson has carefully assembled a highly cohesive and dynamic Senior Leadership team with a strong commitment to the goals, values and priorities of the SKCCC. The Deputy Director and Associate Directors (ADs) have broad responsibilities and work with the Director to plan scientific direction with particular emphasis on Program interaction and translational research. The Deputy Director and ADs have significant oversight responsibilities for the Research Programs and in research training, education, community programs and outreach. Their collective success is evidenced by new strategic initiatives, evolution of Programs, development of Cores, increased transdisciplinary collaboration along the translational pipeline and, in particular, the impact on the SKCCC catchment area. They are continuously focused on the priorities of the SKCCC, including understanding and addressing cancer disparities. SKCCC leadership includes the Director, Deputy Director (Elizabeth M. Jaffee, M.D.), an AD for Clinical Research (Michael A. Carducci, M.D.), an AD for Population Sciences (John D. Groopman, Ph.D.), an AD for Shared Resources (Robert A. Casero, Ph.D.), an AD for Laboratory Research (Kenneth Kinzler, Ph.D.), an AD for Research Training and Education (Ben Park, M.D., Ph.D.), and an AD for Administration (Rosalie W ollett).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-54
Application #
9278330
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
54
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications